Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Apr 11:16:149.
doi: 10.1186/s13063-015-0682-5.

Investigating the non-specific effects of BCG vaccination on the innate immune system in Ugandan neonates: study protocol for a randomised controlled trial

Sarah Prentice  1   2   3 , Emily L Webb  4 , Hazel M Dockrell  5   6   7 , Pontiano Kaleebu  8 , Alison M Elliott  9   10   11 , Stephen Cose  12   13
Affiliations
Randomized Controlled Trial

Investigating the non-specific effects of BCG vaccination on the innate immune system in Ugandan neonates: study protocol for a randomised controlled trial

Sarah Prentice et al. Trials. .

Erratum in

Abstract

Background: The potential for Bacillus Calmette-Guérin (BCG) vaccination to protect infants against non-mycobacterial disease has been suggested by a randomised controlled trial conducted in low birth-weight infants in West Africa. Trials to confirm these findings in healthy term infants, and in a non-West African setting, have not yet been carried out. In addition, a biological mechanism to explain such heterologous effects of BCG in the neonatal period has not been confirmed. This trial aims to address these issues by evaluating whether BCG non-specifically enhances the innate immune system in term Ugandan neonates, leading to increased protection from a variety of infectious diseases.

Methods: This trial will be an investigator-blinded, randomised controlled trial of 560 Ugandan neonates, comparing those receiving BCG at birth with those receiving BCG at 6 weeks of age. This design allows comparison of outcomes between BCG-vaccinated and -naïve infants until 6 weeks of age, and between early and delayed BCG-vaccinated infants from 6 weeks of age onwards. The primary outcomes of the study will be a panel of innate immune parameters. Secondary outcomes will include clinical illness measures.

Discussion: Investigation of the possible broadly protective effects of neonatal BCG immunisation, and the optimal vaccination timing to produce these effects, could have profound implications for public healthcare policy. Evidence of protection against heterologous pathogens would underscore the importance of prioritising BCG administration in a timely manner for all infants, provide advocacy against the termination of BCG's use and support novel anti-tuberculous vaccine strategies that would safeguard such beneficial effects.

Trial registration: ISRCTN59683017 : registration date: 15 January 2014.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram of study procedures.
See this image and copyright information in PMC

References

    1. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367:1173–80. doi: 10.1016/S0140-6736(06)68507-3. - DOI - PubMed
    1. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995;346:1339–45. doi: 10.1016/S0140-6736(95)92348-9. - DOI - PubMed
    1. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet. 2010;375:2110–9. doi: 10.1016/S0140-6736(10)60393-5. - DOI - PubMed
    1. Shann F. The nonspecific effects of vaccines and the expanded program on immunization. J Infect Dis. 2011;204:182–4. doi: 10.1093/infdis/jir244. - DOI - PubMed
    1. Aronson JD. BCG vaccination among American Indians. Am Rev Tuberc. 1948;57:96–9. - PubMed

Publication types

Associated data